Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir
作者： M Shebley , W Fu , P Badri , DAJ Bow , V Fischer
DOI: 10.1002/CPT.689
关键词:
摘要: … clopidogrel acyl‐β‐D glucuronide may not be as potent as previously suggested. The dasabuvir and updated clopidogrel … of dasabuvir when coadministered with clopidogrel. While the …
cyberleninka.org
sci-hub.se 参考文章(33)
Qingqing Xiao, Liling Tang, Ruijuan Xu, Wei Qian, Jin Yang, Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone Biopharmaceutics & Drug Disposition. ,vol. 36, pp. 603- 612 ,(2015) , 10.1002/BDD.1987
Jinping Gan, Weiqi Chen, Hong Shen, Ling Gao, Yang Hong, Yuan Tian, Wenying Li, Yueping Zhang, Yuwei Tang, Hongjian Zhang, William Griffith Humphreys, A. David Rodrigues, Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism British Journal of Clinical Pharmacology. ,vol. 70, pp. 870- 880 ,(2010) , 10.1111/J.1365-2125.2010.03772.X
Eleanor J. Guest, Karen Rowland-Yeo, Amin Rostami-Hodjegan, Geoffrey T. Tucker, J. Brian Houston, Aleksandra Galetin, Assessment of algorithms for predicting drug–drug interactions via inhibition mechanisms: comparison of dynamic and static models British Journal of Clinical Pharmacology. ,vol. 71, pp. 72- 87 ,(2011) , 10.1111/J.1365-2125.2010.03799.X
Manthena V. S. Varma, Jian Lin, Yi-an Bi, Emi Kimoto, A. David Rodrigues, Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide Drug Metabolism and Disposition. ,vol. 43, pp. 1108- 1118 ,(2015) , 10.1124/DMD.115.064303
J. E. Stark, Potential for a Significant Interaction Between Clopidogrel and Dasabuvir Clinical Infectious Diseases. ,vol. 61, pp. 134- 135 ,(2015) , 10.1093/CID/CIV246
A A Mathias, P German, B P Murray, L Wei, A Jain, S West, D Warren, J Hui, B P Kearney, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clinical Pharmacology & Therapeutics. ,vol. 87, pp. 322- 329 ,(2010) , 10.1038/CLPT.2009.228
K CULMMERDEK, L VONMOLTKE, L GAN, K HORAN, R REYNOLDS, J HARMATZ, M COURT, D GREENBLATT, Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clinical Pharmacology & Therapeutics. ,vol. 79, pp. 243- 254 ,(2006) , 10.1016/J.CLPT.2005.11.009
Manthena V. S. Varma, Yurong Lai, Emi Kimoto, Theunis C. Goosen, Ayman F. El-Kattan, Vikas Kumar, Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide Pharmaceutical Research. ,vol. 30, pp. 1188- 1199 ,(2013) , 10.1007/S11095-012-0956-5
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker, Amin Rostami-Hodjegan, The Simcyp® population-based ADME simulator Expert Opinion on Drug Metabolism & Toxicology. ,vol. 5, pp. 211- 223 ,(2009) , 10.1517/17425250802691074
Peter N. Morcos, Linda Chang, Rohit Kulkarni, Mylene Giraudon, Nancy Shulman, Barbara J. Brennan, Patrick F. Smith, Jonathan Q. Tran, A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. European Journal of Clinical Pharmacology. ,vol. 69, pp. 1939- 1949 ,(2013) , 10.1007/S00228-013-1556-Y